Typ-2-Diabetes: Ausschuss für Humanarzneimittel empfiehlt Zulassung von Empagliflozin in Europa
Crossref DOI link: https://doi.org/10.1007/s15034-014-0565-y
Published Online: 2014-05-18
Published Print: 2014-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
red,
Text and Data Mining valid from 2014-04-01
